IntelliCap Oral Drug Delivery System Wins European Innovation Award
News Nov 20, 2014
The IntelliCap electronic oral drug delivery technology, created by medtech innovator Medimetrics, has won a prestigious European ‘High-Tech Innovation Award’ from Accenture, the global management consultancy.
As Medimetrics CEO Olaf Weiner explained: “We are delighted to win this award, in recognition of the unique capabilities of the technology behind our drug delivery systems. The use of IntelliCap will help deliver a revolution in healthcare which both saves costs and improves the outcomes for patients.”
The IntelliCap system was introduced into the market in 2011. An increasing number of pharma companies are using this powerful tool in the early-stage development and life cycle management of drugs. This unique, interactive device enables personalization of medications and treatments, empowering scientists to establish quickly the effective medication dose and delivery requirements. This reduces the risk of failure in expensive, late stage clinical trials, due to lack of safety or efficacy.
While the IntelliCap system is applied to speed the development of new products, the technology’s strength is its ability to enable the development of other pioneering products.
As Dr Weiner added: “The spirit of the award was to recognize the potential of the IntelliCap technology. Its ability to adapt and personalize during delivery will help usher in an era of smart pharmaceuticals to the benefit of patients.”
An early example is in the field of women’s health. LiGalli, a pioneering Dutch company led by Dr. Willem de Laat, is integrating the technology into a novel vaginal drug delivery system that enables new therapies.
In another example, IntelliCap technology creates a means of sampling and mapping content from the small intestine to identify its microbiological composition, in a non-invasive way. The mapping process will provide novel insights into how certain foods and also therapeutic agents might react in the gut and so affect our health.
PhoreMost Completes $15M (£11M) Series-A Round to Enter Drug DiscoveryNews
Investment to fund expansion of operations and progression of drug target pipeline.READ MORE
Abzena Selects Sartorius Stedim Biotech to Equip its US Based Development and Manufacturing SitesNews
Abzena plc, the life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, has selected Sartorius Stedim Biotech as its preferred equipment supplier in the U.S.READ MORE
Drug Combo Prevents Stroke, Shows Promise for ClinicNews
Taking the clot-preventing drug clopidogrel along with aspirin may lower your risk of having a major stroke within the next 90 days following a TIAREAD MORE
Comments | 0 ADD COMMENT
9th International Conference on Mass Spectrometry and Chromatography
Sep 21 - Sep 22, 2018